Reducing the Risk of Congenital CMV

Description

From Knowledge to Action: Reducing the Risk of Congenital CMV 

A Webinar for Pediatric and Primary Care Teams 

Did you know that one in five U.S.-born children with congenital CMV (cCMV) will develop permanent problems such as hearing loss or developmental disabilities? 

cCMV is the most common infectious cause of birth defects in the United States, yet awareness among healthcare professionals remains limited. While most infants born with cCMV do not experience long-term health complications, a significant number can develop serious issues such as hearing loss, vision problems, or developmental delays.

This informative panel discussion will provide pediatricians, primary care providers, and other healthcare professionals with a foundational understanding of the CMV virus, including how it is transmitted and why certain pregnancies are at higher risk. Experts will highlight key risk factors—such as maternal primary infection, reinfection, and reactivation—as well as other transmission routes, including blood transfusion and organ transplantation as well as how to talk with pregnant women about risk factors, transmission, diagnosis, and next steps. 

Attendees will learn:

• The virology and epidemiology of congenital CMV
• Strategies for early identification and counseling of at-risk pregnant patients
• Foster collaboration between families, primary care physicians, pediatricians, and public health advocates to improve education, early detection, and outcomes related to cCMV

Join us for this timely and practical discussion aimed at improving early recognition, risk reduction, and care coordination for families impacted by cCMV.

Presentation by: Dr. Joel Waddell, DO; Pediatric ID Specialist

Panelists:

• Dr. Joel Waddell, DO; Pediatric ID Specialist
• Dr. Patrick Courtney, MD; Family Medicine
• Amanda Devereaux, RN, BSN; previously with the National CMV Foundation and lived experience as a mother with a child born with cCMV

Continuing Education Credit

Des Moines University Medicine and Health Sciences is the accredited provider and has approved this activity for AMA PRA Category 1 Credit™, American Osteopathic Association credit, and continuing education contact hours. The speaker(s) will disclose if any pharmaceuticals, medical procedures, or devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The activity director is responsible for determining educational content and selecting speakers. No ineligible company provided financial support for this continuing education activity. If you have questions regarding continuing education credit, please email cme@dmu.edu.

Sponsored by: